在NSCLC中对免疫检查点抑制剂产生初级耐药性的机制
Georgia Gomatou1, Andriani Charpidou2, Peifeng Li3
1Oncology Unit, Third Department of Medicine, "Sotiria" General Hospital for Chest Diseases, National and Kapodistrian University of Athens, Athens, Greece. georgiagom@med.uoa.gr.
概括
免疫检查点抑制剂 (ICI) 对非小细胞肺癌 (NSCLC) 提供生存益处,但耐药性很常见. 了解原发性耐药机制对于开发用于NSCLC患者的新疗法至关重要.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胸部恶性瘤 胸部恶性瘤
背景情况:
- 免疫检查点抑制剂 (ICI) 已经改变了非小细胞肺癌 (NSCLC) 治疗,改善了存活率和反应耐久性.
- 然而,很大一部分患者会对ICI产生原发性或获得性耐药性.
- 在NSCLC中确定原发性耐药性,特别是随着早期治疗方案的发展,仍然具有挑战性.
研究的目的:
- 审查定义和理解NSCLC中对ICI的原发性耐药性的挑战.
- 探索NSCLC中原发性ICI耐药性的复杂机制.
- 讨论目前的管理策略和未来的研究方向,为NSCLC患者与初级ICI耐药性.
主要方法:
- 关于NSCLC中ICI耐药性的当前研究的文献综述.
- 分析涉及瘤细胞,瘤微环境和宿主因素的机制.
- 讨论临床挑战和治疗策略.
主要成果:
- 在NSCLC中对ICI的主要耐药性是多因素的,涉及瘤和宿主之间的复杂相互作用.
- 免疫抑制性瘤表型是初级抗性的关键特征.
- 在NSCLC中优化初级ICI耐药性的管理是一个未满足的临床需求.
结论:
- 对ICI的初级耐药性是NSCLC治疗中的一个重要障碍.
- 对抗性机制的进一步研究对于治疗进步至关重要.
- 探索替代免疫疗法和新型药物合物有望克服NSCLC中的ICI耐药性.
相关概念视频
Cytotoxic T Cells-mediated Immune Response
858
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
858
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
T Cell Activation and Clonal Selection
686
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
686
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K


